Payment overview · 2025
General Payments
$342.46
18 reported records · 7 companies
Healthcare provider profile · identity verified
Crisanto M Reyes, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MILFORD, IL · NPI 1154461978
Verified facts
What the public records show
CMS Open Payments records show Crisanto M Reyes, M.D. received $342.46 in general payments during 2025 across 18 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 45.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Zenpep by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $154.47 | 45.1% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $55.42 | 16.2% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $37.51 | 10.9% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $35.66 | 10.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $26.99 | 7.9% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.39 | 5.1% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.02 | 4.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $342.46 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $154.47 | 8 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $35.66 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $31.10 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $26.99 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $24.32 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $20.99 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $17.39 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $16.52 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $15.02 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 375 | 82 |
| Atorvastatin Calcium | Atorvastatin Calcium | 323 | 104 |
| Amlodipine Besylate | Amlodipine Besylate | 297 | 80 |
| Lisinopril | Lisinopril | 289 | 77 |
| Tramadol Hcl | Tramadol Hcl | 211 | 44 |
| Omeprazole | Omeprazole | 210 | 50 |
| Potassium Chloride | Potassium Chloride | 191 | 35 |
| Furosemide | Furosemide | 186 | 46 |
| Gabapentin | Gabapentin | 181 | 51 |
| Metformin Hcl | Metformin Hcl | 176 | 58 |
| Metoprolol Tartrate | Metoprolol Tartrate | 161 | 37 |
| Alprazolam | Alprazolam | 159 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 159 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 156 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 154 | 42 |
| Montelukast Sodium | Montelukast Sodium | 142 | 37 |
| Jardiance | Empagliflozin | 134 | 23 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 128 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 128 | 46 |
| Famotidine | Famotidine | 126 | 26 |
| Losartan Potassium | Losartan Potassium | 119 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 118 | 43 |
| Ibuprofen | Ibuprofen | 107 | 36 |
| Azithromycin | Azithromycin | 104 | 76 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 101 | 42 |
| Prednisone | Prednisone | 99 | 67 |
| Fluticasone Propionate | Fluticasone Propionate | 98 | 28 |
| Trazodone Hcl | Trazodone Hcl | 94 | 21 |
| Simvastatin | Simvastatin | 87 | 27 |
| Eliquis | Apixaban | 86 | 19 |
| Spironolactone | Spironolactone | 84 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 83 | 24 |
| Meloxicam | Meloxicam | 80 | 20 |
| Glipizide | Glipizide | 78 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 77 | 23 |
| Carvedilol | Carvedilol | 67 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 67 | 19 |
| Allopurinol | Allopurinol | 66 | 19 |
| Lorazepam | Lorazepam | 66 | 17 |
| Fenofibrate | Fenofibrate | 61 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 60 | 14 |
| Atenolol | Atenolol | 59 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 58 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 56 | 13 |
| Clonazepam | Clonazepam | 53 | suppressed |
| Januvia | Sitagliptin Phosphate | 53 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 53 | 15 |
| Levetiracetam | Levetiracetam | 52 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 52 | 16 |
| Ezetimibe | Ezetimibe | 51 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | 15 |
| Mirtazapine | Mirtazapine | 49 | 14 |
| Warfarin Sodium | Warfarin Sodium | 49 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 48 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 47 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 46 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 45 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 44 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 44 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 43 | 30 |
| Pregabalin | Pregabalin | 42 | suppressed |
| Aripiprazole | Aripiprazole | 40 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 40 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 40 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 38 | 32 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | 12 |
| Cephalexin | Cephalexin | 36 | 27 |
| Lamotrigine | Lamotrigine | 36 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 36 | 12 |
| Donepezil Hcl | Donepezil Hcl | 34 | 16 |
| Nystatin | Nystatin | 34 | 22 |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Bupropion Xl | Bupropion Hcl | 33 | suppressed |
| Memantine Hcl | Memantine Hcl | 32 | suppressed |
| Diazepam | Diazepam | 31 | suppressed |
| Synthroid | Levothyroxine Sodium | 31 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 30 | suppressed |
| Finasteride | Finasteride | 29 | 11 |
| Glimepiride | Glimepiride | 28 | 16 |
| Digoxin | Digoxin | 27 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 24 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 24 | suppressed |
| Latanoprost | Latanoprost | 24 | suppressed |
| Sodium Fluoride | Fluoride (Sodium) | 24 | suppressed |
| Vascepa | Icosapent Ethyl | 24 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 23 | 23 |
| Lovastatin | Lovastatin | 23 | suppressed |
| Daptomycin | Daptomycin | 22 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 22 | suppressed |
| Ertapenem | Ertapenem Sodium | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 16 |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Ketoconazole | Ketoconazole | 19 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 19 | 16 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 15 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Novolog | Insulin Aspart | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Scopolamine | Scopolamine | 17 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 16 | 16 |
| Celecoxib | Celecoxib | 16 | suppressed |
| Clotrimazole | Clotrimazole | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | 11 |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Olanzapine Odt | Olanzapine | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Junel Fe | Norethindrone-E.Estradiol-Iron | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $342.46 · 18 records | Bayer Healthcare Pharmaceuticals Inc. | AIRSUPRA, BREZTRI, CAPLYTA, Cologuard Collection Kit, GVOKE HYPOPEN, Kerendia, VIBERZI, VRAYLAR, ZENPEP | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Zenpep play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error